The National Institutes of Health (NIH) has awarded a four-year, $10 million grant to HudsonAlpha Institute for Biotechnology, a Huntsville, Ala.-based genomics and genetics research institute, in collaboration with the University of Alabama at Birmingham (UAB) School of Medicine and the University of Mississippi Medical Center, to investigate how genome sequencing can help with the diagnosis and care of babies with birth defects and genetic disorders.
The project, “SouthSeq: DNA Sequencing for Newborn Nurseries in the South,” is part of a network of nationwide sites called the Clinical Sequencing Evidence-Generating Research Consortium, or CSER2, and will enroll infants in neonatal nurseries with birth defects and/or other signs suggestive of a genetic disorder. The project is being led by HudsonAlpha Faculty Investigator Greg Cooper, Ph.D., together with HudsonAlpha Faculty Investigator Greg Barsh, M.D. Ph.D.; and Bruce Korf, M.D., Ph.D., professor and chair of the UAB Department of Genetics.
CSER2 expands HudsonAlpha’s existing large-scale DNA sequencing research project, the Clinical Sequencing Exploratory Research Consortium (CSER), also led by Cooper, in which collaborations with UAB and Children’s of Alabama North Alabama Children’s Specialists (NACS) have provided genetic diagnoses for children with intellectual disabilities and developmental delay. To date, the team has sequenced the genomes of almost 500 children with developmental delay and helped to provide more precise clinical diagnoses to nearly 30 percent.
“The previous CSER project allowed HudsonAlpha to develop the infrastructure, knowledge, and partnerships needed for genomic medicine,” Cooper said in a statement. “This new phase of work will build directly upon that foundation, particularly in underserved and diverse populations for whom genomics and genetics have not been accessible.”
For CSER2, the clinical sites will expand beyond North Alabama to focus on infants in hospitals in other regions of the Deep South. Regions include the Birmingham area and Jackson, Miss., where the project directors are Renate Savich, M.D., division chief of Newborn Medicine, and Brian Kirmse, M.D., associate professor of Pediatrics.
“These regional partnerships improve our ability to help children and their families by providing a genetic diagnosis as early as possible,” Barsh said.
“A major goal of CSER2 is to see if we can empower non-genetics trained health professionals to accurately and thoroughly explain the results of genomic testing to families,” UAB’s Korf. said “Because of a shortage of trained medical geneticists and genetic counselors, we need new paradigms in order to provide the benefits of genomic testing to more patients and families. The need is especially acute in our underserved populations, where new models of return of genomic results could be very valuable in community hospital settings.”
The National Human Genome Research Institute (NHGRI) and National Cancer Institute (NCI) have partnered with the National Institute on Minority Health and Health Disparities (NIMHD) to improve the current processes of recruiting patients to be part of the research, testing and follow-up of study participants from diverse racial and ethnic groups, as well as those from currently understudied clinical healthcare settings where genomic medicine might be put into practice.
In the fiscal year 2017, CSER2 is awarding the grants to six clinical sites, which includes HudsonAlpha, and one coordinating center. The awards extend for a total of four years. The clinical sites – all with a goal of recruiting at least 60 percent of participants from diverse or underserved settings – boast research that covers geographical areas from the racially diverse populations in Houston, Texas, to the underrepresented minority populations in Harlem and the Bronx.
With the help of the coordinating center, which assures the organization and logistical support needed to identify new synergies that increase the scientific value of the six individual projects, CSER2 will continue to develop and enhance the evidence base required to bring genome sequencing to non-academic centers, as well as to diverse patient groups.
